BRD2 and central nervous system cancer: In glioma, BRD4 (and not BRD2 or BRD4) sustained the self-renewal of glioma-initiating cells by modulating the Notch1 signaling pathway, and significant inhibition of BRD4 resulted in the loss of stem cell-like properties of glioma cells [198].